During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Dr Kolodziej, national medical director of oncology strategy for Aetna, remarks that the PD-1 agents, including the FDA-approved checkpoint inhibitors pembrolizumab and nivolumab, have generated a great deal of excitement in the oncology community. These drugs are related in terms of their mechanisms of action, and Dr Kolodziej describes the potential opportunity for oral oncolytics to be managed by class effect. Rather than payers deciding whether or not certain drugs will be treated as a class, it is likely that companies or physician groups that develop treatment pathways will recommend a limited number of agents, taking into account safety and efficacy data and drug cost.
Payers’ coverage decisions are currently reflective of FDA approvals and recommendations from the National Comprehensive Cancer Network (NCCN), notes Dr Kolodziej. “Payers tend to respect, at least initially, the FDA label and subsequently expert opinion like that offered by the NCCN. I would say that if a payer made a decision that was in conflict with NCCN, they’d be in a very difficult place to defend that decision.”
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Myasthenia Gravis Care Overlooks Speech and Swallowing Dysfunction
March 9th 2025Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.
Read More
2 Commerce Drive
Cranbury, NJ 08512